Pharmaceuticals, a company focused on targeting muscarinic receptors for the treatment of central nervous system (CNS) disorders including schizophrenia and Alzheimer’s disease, today announced the dosing of the first subject in a tolerability proof-of-concept study of its proprietary lead product KarXT (xanomelineplustrospium chloride). The study, which will be conducted in
What’s the cobalt outlook for 2016? The Investing News Network spoke with industry experts including Chris Berry and Andrew Miller to find out.
Andrew Miller of Benchmark Mineral Intelligence shares his thoughts on what Volkswagen’s electric vehicle announcement could mean for demand for the raw materials needed to make electric vehicle batteries.
A look at the lithium outlook for 2016. Comments from Joe Lowry of Global Lithium, Chris Berry of House Mountain Partners and the Disruptive Discoveries Journal, Andrew Miller of Benchmark Mineral Intelligence and Jon Hykawy of Stormcrow Capital
Benchmark Mineral Intelligence’s World Tour stops in Vancouver, BC on October 1. Will you be attending?